Voronoi Receives Singapore IND Approval for Next-Generation Lung Cancer Targeted Therapy VRN11... Expands Global First-Line EGFR Lung Cancer Clinical Trial
2026.08.18
■ Singapore IND approval following Australia and Hong Kong... Strengthening global first-line treatment clinical network
■ Clinical development strengthened with participation of key physicians as PIs, including at the National Cancer Centre Singapore
Voronoi (310210) disclosed on the 18th that it has received approval from Singapore's Health Sciences Authority (HSA) for the global Phase 1b/2 IND (clinical trial plan) of 'VRN11,' its next-generation EGFR non-small cell lung cancer targeted therapy.
With this approval, the countries in which VRN11's first-line treatment clinical trial is conducted have expanded from Australia and Hong Kong to include Singapore.
Voronoi is pursuing Phase 1b/2 clinical development that includes treatment-naïve patients with EGFR mutation non-small cell lung cancer. Earlier, on the 7th, it submitted a Phase 1b/2 IND to Health Canada, pursuing the expansion of its global clinical trial to North America as well.
The Singapore trial will involve the National Cancer Centre Singapore (NCCS) and Tan Tock Seng Hospital. Dr. Aaron Tan, a thoracic oncology specialist, at NCCS and Dr. Puey Ling Chia at Tan Tock Seng Hospital will each serve as Principal Investigator (PI) and lead the trial.
VRN11 is in a Phase 1a clinical trial in patients whose disease has progressed after administration of existing EGFR targeted therapies. In that trial, Voronoi has confirmed not only efficacy and tolerability but also an intracranial antitumor effect in patients with brain metastases.
A Voronoi representative said, "With the Singapore IND approval, we have further broadened our global first-line treatment clinical network. We are expanding the clinical trial sequentially in major countries and proceeding with the global clinical development of VRN11 without a hitch."
The representative added, "We will secure clinical data in both treatment-naïve patients and patients whose disease has progressed after prior treatment, and continue to demonstrate the differentiated efficacy and safety of VRN11."
■ Clinical development strengthened with participation of key physicians as PIs, including at the National Cancer Centre Singapore
Voronoi (310210) disclosed on the 18th that it has received approval from Singapore's Health Sciences Authority (HSA) for the global Phase 1b/2 IND (clinical trial plan) of 'VRN11,' its next-generation EGFR non-small cell lung cancer targeted therapy.
With this approval, the countries in which VRN11's first-line treatment clinical trial is conducted have expanded from Australia and Hong Kong to include Singapore.
Voronoi is pursuing Phase 1b/2 clinical development that includes treatment-naïve patients with EGFR mutation non-small cell lung cancer. Earlier, on the 7th, it submitted a Phase 1b/2 IND to Health Canada, pursuing the expansion of its global clinical trial to North America as well.
The Singapore trial will involve the National Cancer Centre Singapore (NCCS) and Tan Tock Seng Hospital. Dr. Aaron Tan, a thoracic oncology specialist, at NCCS and Dr. Puey Ling Chia at Tan Tock Seng Hospital will each serve as Principal Investigator (PI) and lead the trial.
VRN11 is in a Phase 1a clinical trial in patients whose disease has progressed after administration of existing EGFR targeted therapies. In that trial, Voronoi has confirmed not only efficacy and tolerability but also an intracranial antitumor effect in patients with brain metastases.
A Voronoi representative said, "With the Singapore IND approval, we have further broadened our global first-line treatment clinical network. We are expanding the clinical trial sequentially in major countries and proceeding with the global clinical development of VRN11 without a hitch."
The representative added, "We will secure clinical data in both treatment-naïve patients and patients whose disease has progressed after prior treatment, and continue to demonstrate the differentiated efficacy and safety of VRN11."